162 related articles for article (PubMed ID: 36683579)
1. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Sadeghi M; Khodakarami A; Ahmadi A; Fathi M; Gholizadeh Navashenaq J; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Movasaghpour Akbari AA; Jadidi-Niaragh F
Expert Opin Ther Targets; 2022 Dec; 26(12):1057-1071. PubMed ID: 36683579
[TBL] [Abstract][Full Text] [Related]
2. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment.
Hemminki K; Hemminki J; Försti A; Sud A
Leukemia; 2023 Apr; 37(4):854-863. PubMed ID: 36828868
[TBL] [Abstract][Full Text] [Related]
3. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Huang LW; Wong SW; Andreadis C; Olin RL
Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.
Caivano A; La Rocca F; Simeon V; Girasole M; Dinarelli S; Laurenzana I; De Stradis A; De Luca L; Trino S; Traficante A; D'Arena G; Mansueto G; Villani O; Pietrantuono G; Laurenti L; Del Vecchio L; Musto P
Cell Oncol (Dordr); 2017 Feb; 40(1):97-103. PubMed ID: 27761889
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
8. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders.
Caivano A; Laurenzana I; De Luca L; La Rocca F; Simeon V; Trino S; D'Auria F; Traficante A; Maietti M; Izzo T; D'Arena G; Mansueto G; Pietrantuono G; Laurenti L; Musto P; Del Vecchio L
Tumour Biol; 2015 Dec; 36(12):9739-52. PubMed ID: 26156801
[TBL] [Abstract][Full Text] [Related]
9. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
11. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
12. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
13. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Findings of Haematological Malignancies in Hospital Admitted Patients.
Islam AS; Ara ZG; Bhuiyan GR; Khan AU; Khan MM
Mymensingh Med J; 2021 Jan; 30(1):28-34. PubMed ID: 33397847
[TBL] [Abstract][Full Text] [Related]
15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.
Rozenfeld-Granot G; Toren A; Amariglio N; Brok-Simoni F; Rechavi G
Exp Hematol; 2001 Feb; 29(2):228-33. PubMed ID: 11166462
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitors in AML: are we there yet?
Ghosh A; Barba P; Perales MA
Br J Haematol; 2020 Jan; 188(1):159-167. PubMed ID: 31808941
[TBL] [Abstract][Full Text] [Related]
18. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Bernard MP; Bancos S; Sime PJ; Phipps RP
Curr Pharm Des; 2008; 14(21):2051-60. PubMed ID: 18691115
[TBL] [Abstract][Full Text] [Related]
19. Incidence and survival of hematological cancers among adults ages ≥75 years.
Krok-Schoen JL; Fisher JL; Stephens JA; Mims A; Ayyappan S; Woyach JA; Rosko AE
Cancer Med; 2018 Jul; 7(7):3425-3433. PubMed ID: 29654631
[TBL] [Abstract][Full Text] [Related]
20. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies.
Hock BD; Starling GC; Patton WN; Salm N; Bond K; McArthur LT; McKenzie JL
Leuk Lymphoma; 2004 Oct; 45(10):2111-8. PubMed ID: 15370258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
